NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Bilateral Orthotopic Lung Transplant - Bone Marrow Transplant

Phase 1

Completed

Conditions: Primary Immunodeficiency
PID

Interventions: Biological: CD3/CD19 neg allogeneic BMT

First Posted Date: 2017-11-06

Last Posted Date: 2024-04-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 5

Registration Number: NCT03330795

Locations: 🇺🇸
Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

Age and Response to Flu Vaccines

Phase 4

Completed

Conditions: Influenza
Influenza Immunisation

Interventions: Biological: Influenza Virus Quadrivalent Inactivated Vaccine

First Posted Date: 2017-11-01

Last Posted Date: 2021-05-24

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 152

Registration Number: NCT03328325

Locations: 🇺🇸
Rochester General Hospital - Infectious Disease Unit, Rochester, New York, United States
🇺🇸
University of Rochester Medical Center - Strong Memorial Hospital - Infectious Diseases, Rochester, New York, United States

Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4

Phase 2

Completed

Conditions: Influenza
Influenza Immunisation
Avian Influenza

Interventions: Drug: AS03
Biological: Inactivated influenza H7N9 vaccine
Biological: Influenza Virus Quadrivalent Inactivated Vaccine
Other: Phosphate Buffered Saline (PBS) diluent

First Posted Date: 2017-10-23

Last Posted Date: 2020-08-06

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 149

Registration Number: NCT03318315

Locations: 🇺🇸
University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore, Maryland, United States
🇺🇸
University of Alabama at Birmingham School of Medicine - Alabama Vaccine Research Clinic, Birmingham, Alabama, United States
🇺🇸
Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati, Ohio, United States

and more 1 locations

Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency

Phase 1

Conditions: X-Linked Combined Immunodeficiency Diseases

Interventions: Biological: CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1α-hγc-OPT
Drug: Palifermin
Drug: Busulfan

First Posted Date: 2017-10-19

Last Posted Date: 2019-12-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 13

Registration Number: NCT03315078

Locations: 🇺🇸
Laboratory of Host Defenses (LHD), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, United States

Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly

Phase 2

Completed

Conditions: Avian Influenza
Influenza Immunisation

Interventions: Biological: Inactivated influenza H7N9 vaccine
Drug: AS03
Other: Phosphate Buffered Saline (PBS) diluent

First Posted Date: 2017-10-17

Last Posted Date: 2023-10-24

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 720

Registration Number: NCT03312231

Locations: 🇺🇸
Duke Vaccine and Trials Unit, Durham, North Carolina, United States
🇺🇸
University of Iowa - Vaccine Research and Education Unit, Iowa City, Iowa, United States
🇺🇸
The Hope Clinic of Emory University, Decatur, Georgia, United States

and more 2 locations

Molecular Basis of Erythrocyte Invasion by Plasmodium Vivax Into Duffy-Negative Erythrocytes in Mali

Completed

Conditions: Malaria

First Posted Date: 2017-10-09

Last Posted Date: 2023-10-31

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 667

Registration Number: NCT03304691

Locations: 🇲🇱
Yirimadio Community Health Center, Bamako, Mali
🇲🇱
Bandiagara Malaria Program (BMP) Clinic, Bandiagara, Mali

Community Dynamics of Malaria Transmission and Mosquito Feeding in Bancoumana, Mali

Completed

Conditions: Malaria

First Posted Date: 2017-10-09

Last Posted Date: 2024-12-19

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1928

Registration Number: NCT03304704

Locations: 🇲🇱
Doneguebougou Facility, Doneguebougou, Mali
🇲🇱
Bancoumana Malaria Vaccine Center, Bamako, Mali
🇲🇱
Univ of Sciences, Techniques and Technology, Bamako, Mali

Asymptomatic Congenital CMV Treatment

Phase 2

Terminated

Conditions: Congenital Cytomegalovirus Infection

Interventions: Drug: Valganciclovir

First Posted Date: 2017-10-04

Last Posted Date: 2023-01-26

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 7

Registration Number: NCT03301415

Locations: 🇺🇸
University of Alabama - Children's of Alabama - Clinical Virology, Birmingham, Alabama, United States
🇺🇸
Arkansas Children's Hospital - Infectious Diseases, Little Rock, Arkansas, United States
🇺🇸
University of Louisville School of Medicine - Norton Children's Hospital - Infectious Diseases, Louisville, Kentucky, United States

and more 6 locations

PREDICT Cytomegalovirus (CMV)

Completed

Conditions: Lung Transplant

Interventions: Other: Procedure

First Posted Date: 2017-10-04

Last Posted Date: 2020-08-06

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 84

Registration Number: NCT03300882

Locations: 🇺🇸
Johns Hopkins Hospital: Transplantation, Baltimore, Maryland, United States
🇨🇦
Toronto General Hospital: Transplantation, Toronto, Canada
🇺🇸
Duke University Medical Center: Transplantation, Durham, North Carolina, United States

and more 1 locations

A Safety, Tolerability, Pharmacokinetics and Immunogenicity Trial of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051

Phase 1

Completed

Conditions: Corona Virus Infection

Interventions: Other: Placebo
Biological: REGN3048
Biological: REGN3051

First Posted Date: 2017-10-04

Last Posted Date: 2019-02-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 48

Registration Number: NCT03301090

Locations: 🇺🇸
WCCT Global Cypress Clinical Pharmacology Unit, Cypress, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy